AU2907700A - Use of desoxypeganine in the treatment of alzheimer's dementia - Google Patents

Use of desoxypeganine in the treatment of alzheimer's dementia

Info

Publication number
AU2907700A
AU2907700A AU29077/00A AU2907700A AU2907700A AU 2907700 A AU2907700 A AU 2907700A AU 29077/00 A AU29077/00 A AU 29077/00A AU 2907700 A AU2907700 A AU 2907700A AU 2907700 A AU2907700 A AU 2907700A
Authority
AU
Australia
Prior art keywords
desoxypeganine
dementia
alzheimer
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU29077/00A
Other languages
English (en)
Inventor
Bodo Asmussen
Thomas Hille
Hans-Rainer Hoffmann
Klaus Opitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of AU2907700A publication Critical patent/AU2907700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU29077/00A 1999-02-19 2000-02-08 Use of desoxypeganine in the treatment of alzheimer's dementia Abandoned AU2907700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19906975A DE19906975B4 (de) 1999-02-19 1999-02-19 Arzneiform zur Behandlung von Alzheimer'scher Demenz
DE19906975 1999-02-19
PCT/EP2000/000972 WO2000048599A1 (de) 1999-02-19 2000-02-08 Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz

Publications (1)

Publication Number Publication Date
AU2907700A true AU2907700A (en) 2000-09-04

Family

ID=7898022

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29077/00A Abandoned AU2907700A (en) 1999-02-19 2000-02-08 Use of desoxypeganine in the treatment of alzheimer's dementia

Country Status (10)

Country Link
US (1) US6436937B1 (enExample)
EP (1) EP1152762B8 (enExample)
JP (1) JP2002537256A (enExample)
KR (1) KR20010102219A (enExample)
AT (1) ATE294584T1 (enExample)
AU (1) AU2907700A (enExample)
DE (2) DE19906975B4 (enExample)
ES (1) ES2242605T3 (enExample)
PT (1) PT1152762E (enExample)
WO (1) WO2000048599A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
WO2002017920A2 (en) * 2000-08-28 2002-03-07 Sention, Inc Use of methylphenidate compounds to enhance memory
WO2002017919A2 (en) * 2000-08-28 2002-03-07 Sention, Inc. Use of threo-methylphenidate compounds to enhance memory
DE10119863A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen
DE10163667B4 (de) * 2001-12-21 2006-10-26 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
RU2005103398A (ru) * 2002-07-09 2006-06-27 Актелион Фармасьютикалз Лтд. (Ch) Производные 7,8,9,10-тетрагидро-6h-азепино-, 6,7,8,9-тетрагидропиридо-и 2,3-дигидро-2h-пирроло-[2,1-b]-хиназолинона
DE10304141B4 (de) 2003-02-03 2006-03-09 Hf Arzneimittelforschung Gmbh Verfahren zur Herstellung von Chinazolin-Alkaloiden
DE10354893B4 (de) * 2003-11-24 2011-03-10 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
CN101433565B (zh) * 2008-11-26 2013-06-05 上海中医药大学 骆驼蓬属种子总生物碱提取物和它们的制备

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU605614A1 (ru) * 1971-10-20 1978-05-05 Ордена Трудового Красного Знамени Институт Химии Растительных Веществ Ан Узбекской Сср Антихолинэстеразное средство
SU878295A1 (ru) * 1979-07-04 1981-11-07 Ордена Трудового Красного Знамени Институт Химии Растительных Веществ Ан Узсср Способ получени дезоксипеганина гидрохлорида
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
SE9504618D0 (sv) * 1995-12-22 1995-12-22 Astra Ab New Compounds

Also Published As

Publication number Publication date
US6436937B1 (en) 2002-08-20
ATE294584T1 (de) 2005-05-15
KR20010102219A (ko) 2001-11-15
JP2002537256A (ja) 2002-11-05
EP1152762A1 (de) 2001-11-14
WO2000048599A1 (de) 2000-08-24
PT1152762E (pt) 2005-08-31
DE50010234D1 (de) 2005-06-09
DE19906975B4 (de) 2004-04-15
DE19906975A1 (de) 2000-08-24
ES2242605T3 (es) 2005-11-16
EP1152762B1 (de) 2005-05-04
EP1152762B8 (de) 2005-06-29

Similar Documents

Publication Publication Date Title
AU2003284968A1 (en) Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
AU1402895A (en) Use of pla2 inhibitors as treatment for alzheimer's disease
AU5716898A (en) Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
WO2001028494A3 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
UA41355C2 (uk) Засіб для лікування нейро-сніду
AU2003277010A1 (en) A method and system for detecting the effects of alzheimer's disease in the human retina
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
EP1152762B8 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
AU7606596A (en) The use of aliphatic carboxylic acid derivatives in ophthalmic disorders
AU2001265186A1 (en) Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
PL338673A1 (en) Application of fanquinone in treating alzheimer disease
AU2620600A (en) Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
AU4707101A (en) Method and system for online third party referral system customized to the purchaser's needs
CA2260863A1 (en) Treatment of psychotic disorders
AU2003237657A1 (en) Means and methods for improved treatment using "setrones"
AU7653600A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
GB9802542D0 (en) New use
AU2566201A (en) Compounds and methods for the treatment of pain
AU2420101A (en) Method and composition for the treatment of pain
AU1101301A (en) 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
AU2420201A (en) Compounds and methods for the treatment of pain
EP1036795A3 (en) Process for preparing ascorbic acid-2-monophosphate salt

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase